Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ORMP Stock Forecast 2026-2027
$3.71
Current Price
$151.84M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ORMP Price Targets
+68.5%
To High Target of $6.25
+68.5%
To Median Target of $6.25
+68.5%
To Low Target of $6.25
ORMP Price Momentum
-4.6%
1 Week Change
-9.3%
1 Month Change
+67.1%
1 Year Change
+30.2%
Year-to-Date Change
-25.9%
From 52W High of $5.01
+87.4%
From 52W Low of $1.98
📊 TOP ANALYST CALLS
Did ORMP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Oramed is one of their latest high-conviction picks.
Latest ORMP Stock Price Targets & Analyst Predictions
ORMP has shown a year-to-date change of 30.2% and a 1-year change of 67.1%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ORMP. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ORMP Analyst Ratings
0
Buy
0
Hold
0
Sell
ORMP Price Target Range
Low
$6.25
Average
$6.25
High
$6.25
Current: $3.71
Latest ORMP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ORMP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $N/A |
| May 20, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| May 17, 2023 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Jan 17, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Jan 12, 2023 | Canaccord Genuity | Hold | Downgrade | $N/A | |
| May 16, 2022 | Aegis Capital | Buy | Maintains | $N/A | |
| Feb 18, 2022 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 30, 2021 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 29, 2021 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 2, 2021 | Aegis Capital | Buy | Maintains | $N/A | |
| Jul 29, 2021 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jun 8, 2021 | Aegis Capital | Buy | Maintains | $N/A | |
| Apr 20, 2021 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Feb 9, 2021 | National Securities Corporation | Buy | Initiates | $N/A | |
| Jan 27, 2021 | Aegis Capital | Buy | Maintains | $N/A | |
| Jul 13, 2020 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 22, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 11, 2019 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Nov 19, 2015 | FBR Capital | Outperform | Initiates | $N/A | |
| Oct 1, 2015 | H.C. Wainwright | Buy | Initiates | $N/A |
Oramed Pharmaceuticals Inc. (ORMP) Competitors
The following stocks are similar to Oramed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oramed Pharmaceuticals Inc. (ORMP) Financial Data
Oramed Pharmaceuticals Inc. has a market capitalization of $151.84M with a P/E ratio of 1.4x. The company generates $2.00M in trailing twelve-month revenue with a 0.7% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +3,766.2% and return on equity of +58.2%.
Valuation Metrics
Market Cap
$151.84M
Enterprise Value
$86.76M
P/E Ratio
1.4x
PEG Ratio
0.0x
Price/Sales
75.9x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+3,766.2%
Net Margin
+0.7%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+43.4%
Current Ratio
6.5x
Debt/Equity
0.3x
ROE
+58.2%
ROA
-4.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Oramed Pharmaceuticals Inc. (ORMP) Business Model
About Oramed Pharmaceuticals Inc.
What They Do
Biotechnology company developing oral drug delivery systems.
Business Model
Oramed Pharmaceuticals generates revenue by innovating and commercializing oral drug delivery technologies, specifically targeting proteins that typically require injections. By focusing on transforming these injectable treatments into oral forms, the company aims to enhance patient compliance and expand market opportunities in chronic disease management.
Additional Information
The company is headquartered in Jerusalem, Israel, and is recognized for its proprietary Protein Oral Delivery (POD) technology. Oramed's pipeline includes advancements in diabetes treatment, particularly the development of oral insulin, indicating its potential to significantly impact patient care and the healthcare industry as a whole.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Nadav Kidron Esq.
Country
United States
IPO Year
2007
Website
www.oramed.comOramed Pharmaceuticals Inc. (ORMP) Latest News & Analysis
Latest News
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
17 days ago
Quick Summary
Oramed Pharmaceuticals downgraded to 'Hold' after failed ORMD-0801 trial. It pivots to target specific T2D patients and transfers POD Tech to Lifeward, amid concerns over cash burn and funding.
Why It Matters
Oramed's downgrade reflects failed trials, impacting stock value. The pivot and new partnerships offer revenue potential, but cash burn raises concerns about financial stability and funding.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Lifeward Ltd. is positioning itself as a diversified biomedical innovation company, integrating Oramed's oral delivery technology and gaining access to $47 million for clinical development.
Why It Matters
Lifeward's integration of Oramed's technology and potential access to $47 million enhances its growth prospects, signaling a strategic move into profitable biotech markets.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lifeward secures up to $47 million from Oramed to enhance its MedTech platform and acquire oral delivery technology, targeting the $600 billion injectable drug market.
Why It Matters
Lifeward's acquisition of Oramed's POD™ technology and strategic investment signals a strong growth trajectory, enhancing its MedTech portfolio and accessing a lucrative $600 billion market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Oramed and Lifeward Announce Strategic Transaction
4 months ago
Quick Summary
Oramed will transfer its POD™ technology to Lifeward, gaining a 49.9% ownership stake. Lifeward, led by CEO Mark Grant, aims for profitability, having generated $26M in revenue recently.
Why It Matters
Oramed's transfer of its POD™ platform to Lifeward and acquisition of a 49.9% stake enhances its revenue potential and positions it in the growing medical robotics market, boosting investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, fulfilling an Option Agreement. Oramed's total returns from the investment now stand at $118 million, with more expected.
Why It Matters
Oramed's $18 million payment from Scilex indicates strong returns on investment, enhancing liquidity and potential for future profits through outstanding debt and royalties.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oramed is moving forward with a new trial targeting elderly patients with low BMI and high HbA1c after previous FDA failures. Positive results from a Chinese partner support this strategy.
Why It Matters
Oramed's focus on a specific patient subset following previous trial failures indicates potential for future success, which could impact stock performance and investor sentiment positively.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ORMP Stock
What is Oramed Pharmaceuticals Inc.'s (ORMP) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Oramed Pharmaceuticals Inc. (ORMP) has a median price target of $6.25. The highest price target is $6.25 and the lowest is $6.25.
Is ORMP stock a good investment in 2026?
Analyst ratings for ORMP are not currently available. The stock is currently trading at $3.71. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ORMP stock?
Wall Street analysts predict ORMP stock could reach $6.25 in the next 12 months. This represents a 68.5% increase from the current price of $3.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oramed Pharmaceuticals Inc.'s business model?
Oramed Pharmaceuticals generates revenue by innovating and commercializing oral drug delivery technologies, specifically targeting proteins that typically require injections. By focusing on transforming these injectable treatments into oral forms, the company aims to enhance patient compliance and expand market opportunities in chronic disease management.
What is the highest forecasted price for ORMP Oramed Pharmaceuticals Inc.?
The highest price target for ORMP is $6.25 from at , which represents a 68.5% increase from the current price of $3.71.
What is the lowest forecasted price for ORMP Oramed Pharmaceuticals Inc.?
The lowest price target for ORMP is $6.25 from at , which represents a 68.5% increase from the current price of $3.71.
What is the overall ORMP consensus from analysts for Oramed Pharmaceuticals Inc.?
Analyst ratings for ORMP are not currently available. The stock is trading at $3.71.
How accurate are ORMP stock price projections?
Stock price projections, including those for Oramed Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 2:01 PM UTC